Moolec Science SA has released its unaudited pro forma condensed combined financial statements, providing insights into the financial aspects following its strategic business combination with Bioceres Group, Gentle Tech, and Nutrecon. This merger and acquisition transaction, formalized on June 16, 2025, has resulted in an expanded company structure with Moolec as the parent entity. The financial statements, prepared under the acquisition method of accounting in accordance with IFRS 3, reflect the historical financial data of Moolec and Bioceres Group. The statements are intended to aid stakeholders in analyzing the financial implications of the business combination, although they do not include potential cost savings or synergies expected post-integration. The pro forma adjustments are based on current information and assumptions, with actual future adjustments potentially differing significantly.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.